Phase 2
N=17
Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
Limbal Stem Cell Deficiency
Bottom Line
View on ClinicalTrials.gov: NCT02592330 ↗Enrolled (actual)
17
Serious AEs
5.9%
Results posted
Jan 2025
Primary outcome: Primary: Primary Safety Events of Interest — 1; 0; 0; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft (Procedure); Cultivation of Limbal epithelial cells into a graft (Biological); CALEC Transplant (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Massachusetts Eye and Ear Infirmary
- Primary completion
- Mar 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Primary Safety Events of Interest |
1; 0; 0; 0; 0; 0 | — |
| PRIMARY Manufacturing Feasibility Measures |
14 | — |
| SECONDARY Measure of Transplant Efficacy |
7; 1; 11; 0; 10; 1 | — |
Summary
The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.
Eligibility Criteria
Inclusion Criteria
- Male or female participants age 18 to <90 years old at time of enrollment
- Ability of a subject or guardian/legal representative to provide written informed consent and to comply with study assessments for the full duration of the study.
- Patients with unilateral limbal stem cell deficiency (LSCD) as determined by conjunctivalization of the cornea defined by fibrovascular pannus more than 2 mm from the limbus for greater than or equal to 6 clock hours.
- Additional optional criteria:
- Lack of limbal palisades of Vogt for greater than or equal to 9 clock hours
- Goblet cell presence as defined by impression cytologic criteria
Exclusion Criteria
- Corneal or ocular surface infection within 30 days prior to study entry or CALEC transplantation
- Ocular surface malignancy
- Uncontrolled diabetes with most recent HgA1c greater than 8.5%
- Renal Failure with eGFR below 60 mL/min per 1.73 m2
- Aspartate aminotransferase and alanine aminotransferase levels greater than 3 times institutional upper limit of normal
- Total bilirubin greater than 2 times institutional upper limit of normal (except patients with known Gilbert's syndrome)
- Platelet levels less than 100, 000 or greater than 450,000 per microliter
- Hemoglobin levels of less than 11.0 g/dL in men or less than 10.0 g/dL in women
- Prothrombin time greater than 16 seconds and activated partial thromboplastin time greater than 35 seconds in patients not taking warfarin and an international normalized ratio greater than 3 in patients taking warfarin
- Inability to tolerate monitored anesthesia
- HIV infection or AIDS
- Active Hepatitis B or C
- Pregnancy (positive test) or lactation
- Participation in another simultaneous medical investigation or trial
- Severe cicatricial eye disease
- Severe dry eye disease as determined by Schirmer's test less than 1mm in at least one eye.
- Any medical, psychiatric, debilitating disease/disorder or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
- Signs of current infection, including fever and current treatment with antibiotics.
- History of allo-limbal transplantation
- Presence of allergy to the CALEC graft or any of the chemical components within its formulation.
Exclusion Based on Donor Eye:
- Conjunctivalization of the cornea defined by fibrovascular pannus more than 2 mm from the limbus for greater than or equal to 3 clock hours
- Lack of limbal palisades of Vogt for greater than or equal to 3 clock hours
- History of allo-limbal transplantation
Data sourced from ClinicalTrials.gov (NCT02592330). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.